Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2024 |
| Income Tax Disclosure [Abstract] |
|
| Components of Income (Loss) Before Income Taxes |
For the years ended December 31, 2023 and 2024, income (loss) before income taxes includes the following components (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
|
2023 |
|
|
2024 |
|
|
|
(Restated) |
|
|
|
|
United States |
|
$ |
4,187 |
|
|
$ |
(8,245 |
) |
Foreign |
|
|
(60,799 |
) |
|
|
(68,061 |
) |
Loss before income taxes |
|
$ |
(56,612 |
) |
|
$ |
(76,306 |
) |
|
|
|
|
|
|
|
|
| Schedule of (Benefit) Provision of Income Taxes |
For the years ended December 31, 2023 and 2024, the provision for income taxes consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
|
2023 |
|
|
2024 |
|
|
|
(Restated) |
|
|
|
|
Current: |
|
|
|
|
|
|
U.S. federal |
|
$ |
3,647 |
|
|
$ |
(3,801 |
) |
State |
|
|
154 |
|
|
|
(478 |
) |
Foreign |
|
|
885 |
|
|
|
917 |
|
Current tax provision (benefit) |
|
|
4,686 |
|
|
|
(3,362 |
) |
Deferred: |
|
|
|
|
|
|
U.S. federal |
|
$ |
5,820 |
|
|
$ |
— |
|
State |
|
|
844 |
|
|
|
— |
|
Foreign |
|
|
6,118 |
|
|
|
1,508 |
|
Deferred tax provision |
|
|
12,782 |
|
|
|
1,508 |
|
Provision (benefit) for income taxes |
|
$ |
17,468 |
|
|
$ |
(1,854 |
) |
|
|
|
|
|
|
|
|
| Computation of (Benefit) Provision of Income Taxes Reconciliation |
The table below reconciles the Company's tax (benefit) provision for income taxes based on the statutory U.S. federal income tax rate to its effective tax rate for the years ended December 31, 2023 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
|
|
2023 |
|
|
2024 |
|
|
|
|
(Restated) |
|
|
|
|
Income tax benefit at federal statutory rate |
|
|
$ |
(11,889 |
) |
|
$ |
(16,024 |
) |
State and local income taxes, net of federal benefit on current year earnings |
|
|
|
154 |
|
|
|
68 |
|
Tax rate changes |
|
|
|
(1,255 |
) |
|
|
— |
|
Valuation allowance changes |
|
|
|
37,283 |
|
|
|
12,345 |
|
Foreign rate differential |
|
|
|
(1,665 |
) |
|
|
(2,454 |
) |
Withholding tax on non-permanent investment in subsidiaries |
|
|
|
— |
|
|
|
1,508 |
|
Research and development |
|
|
|
(2,385 |
) |
|
|
(278 |
) |
Share-based compensation |
|
|
|
311 |
|
|
|
1,203 |
|
Foreign derived intangible income |
|
|
|
(2,887 |
) |
|
|
(199 |
) |
Return to provision and impact of method change (Federal, State and Foreign) |
|
|
|
— |
|
|
|
2,730 |
|
Tax expense related to impairment |
|
|
|
— |
|
|
|
25 |
|
Other |
|
|
|
(199 |
) |
|
|
(778 |
) |
Provision (benefit) for income taxes |
|
|
$ |
17,468 |
|
|
$ |
(1,854 |
) |
|
|
|
|
|
|
|
|
|
| Schedule of Deferred Tax Assets and Liabilities |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities at December 31, 2023 and 2024 were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
|
2023 |
|
|
2024 |
|
|
|
(Restated) |
|
|
|
|
Net operating losses |
|
$ |
19,880 |
|
|
$ |
37,162 |
|
Tax credit carryforwards |
|
|
2,867 |
|
|
|
4,192 |
|
Capitalized research costs |
|
|
11,896 |
|
|
|
— |
|
Disallowed interest carryforwards |
|
|
784 |
|
|
|
1,580 |
|
Lease liability |
|
|
1,194 |
|
|
|
1,991 |
|
Property and equipment |
|
|
— |
|
|
|
1,569 |
|
Share-based compensation |
|
|
3,758 |
|
|
|
4,509 |
|
Intangible assets |
|
|
247 |
|
|
|
3,371 |
|
Other |
|
|
505 |
|
|
|
670 |
|
Subtotal |
|
|
41,131 |
|
|
|
55,044 |
|
Less: Valuation allowance |
|
|
(38,611 |
) |
|
|
(50,956 |
) |
Net deferred tax assets |
|
|
2,520 |
|
|
|
4,088 |
|
Property and equipment |
|
|
(846 |
) |
|
|
— |
|
Operating lease assets |
|
|
(1,133 |
) |
|
|
(1,061 |
) |
Prepaid expenses and other assets |
|
|
(223 |
) |
|
|
(377 |
) |
Capitalized software development costs |
|
|
(318 |
) |
|
|
(2,650 |
) |
Deferred tax liability on foreign investments |
|
|
— |
|
|
|
(1,508 |
) |
Net deferred tax liabilities |
|
|
(2,520 |
) |
|
|
(5,596 |
) |
Total deferred tax assets (liabilities), net |
|
$ |
— |
|
|
$ |
(1,508 |
) |
|
|
|
|
|
|
|
|
| Summary of Valuation Allowance on Deferred Tax Assets |
For the years ended December 31, 2023 and 2024, the following table reflects the activity in the Company’s valuation allowance on deferred tax assets (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
|
2023 |
|
|
2024 |
|
|
|
(Restated) |
|
|
|
|
Beginning balance |
|
$ |
1,328 |
|
|
$ |
38,611 |
|
Increase in valuation allowance |
|
|
37,283 |
|
|
|
12,345 |
|
Total valuation allowance on deferred tax assets |
|
$ |
38,611 |
|
|
$ |
50,956 |
|
|
|
|
|
|
|
|
|
| Summary of Gross Income Tax NOL Carryforwards |
The Company has gross income tax NOL carryforwards related to its U.S. and international operations.
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
2023 |
|
|
2024 |
|
|
(Restated) |
|
|
|
Unlimited carryforward |
|
$85.9 million |
|
|
$151.9 million |
10 to 15 year carryforward |
|
|
— |
|
|
$1.8 million |
20 year carryforward |
|
$1.6 million |
|
|
$5.1 million |
|
| Summary of Tax Credit Carryforwards |
The Company has tax credit carryforwards related to research and development.
|
|
|
|
|
|
|
|
|
Years ended December 31, |
|
|
2023 |
|
|
2024 |
Unlimited carryforward |
|
$2.9 million |
|
|
$3.3 million |
20 year carryforward |
|
|
— |
|
|
$0.9 million |
|
| Summary of Gross Corporate Interest Restriction (CIR) Carryforwards |
The Company has gross corporate interest restriction (“CIR”) disallowance carryforwards related to its UK operations.
|
|
|
|
|
|
|
Years ended December 31, |
|
|
2023 |
|
2024 |
Unlimited carryforward |
|
$3.1 million |
|
$6.3 million |
|